S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
Obama’s 2024 Confession (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Biden Out, _______ In? (Ad)
FMC stock just set a new ceiling higher, 50% higher indeed
Airbnb stock bulls just went all in before earnings
Biden Out, _______ In? (Ad)
Recession risks are fading, business economists say, but political tensions pose threat to economy
Stock market today: World shares mostly higher after S&P 500 tops 5,000
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
Obama’s 2024 Confession (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Biden Out, _______ In? (Ad)
FMC stock just set a new ceiling higher, 50% higher indeed
Airbnb stock bulls just went all in before earnings
Biden Out, _______ In? (Ad)
Recession risks are fading, business economists say, but political tensions pose threat to economy
Stock market today: World shares mostly higher after S&P 500 tops 5,000
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
Obama’s 2024 Confession (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Biden Out, _______ In? (Ad)
FMC stock just set a new ceiling higher, 50% higher indeed
Airbnb stock bulls just went all in before earnings
Biden Out, _______ In? (Ad)
Recession risks are fading, business economists say, but political tensions pose threat to economy
Stock market today: World shares mostly higher after S&P 500 tops 5,000
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
Obama’s 2024 Confession (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Biden Out, _______ In? (Ad)
FMC stock just set a new ceiling higher, 50% higher indeed
Airbnb stock bulls just went all in before earnings
Biden Out, _______ In? (Ad)
Recession risks are fading, business economists say, but political tensions pose threat to economy
Stock market today: World shares mostly higher after S&P 500 tops 5,000

Royalty Pharma (RPRX) Earnings Date, Estimates & Call Transcripts

$29.26
+0.56 (+1.95%)
(As of 02/9/2024 08:56 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Feb. 15
Before Market Opens
Confirmed
Actual EPS
(Nov. 8)
$0.79 Missed By -$0.02
Consensus EPS
(Nov. 8)
$0.81
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

RPRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RPRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Royalty Pharma Analyst EPS Estimates

Current Year EPS Consensus Estimate:$4.24 EPS
Next Year EPS Consensus Estimate: $3.77 EPS

RPRX Earnings Date and Information

Royalty Pharma last posted its earnings data on November 8th, 2023. The biopharmaceutical company reported $0.79 earnings per share for the quarter, missing analysts' consensus estimates of $0.81 by $0.02. The business had revenue of $637 million for the quarter, compared to analyst estimates of $640.96 million. Royalty Pharma has generated $0.31 earnings per share over the last year ($0.31 diluted earnings per share) and currently has a price-to-earnings ratio of 94.4. Earnings for Royalty Pharma are expected to decrease by -11.08% in the coming year, from $4.24 to $3.77 per share. Royalty Pharma has confirmed that its next quarterly earnings report will be published on Thursday, February 15th, 2024. Royalty Pharma will be holding an earnings conference call on Thursday, February 15th at 8:00 AM Eastern. Interested parties can register for or listen to the call..

Royalty Pharma Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/15/2024
Confirmed)		-------  
11/8/2023Q3 2023$0.81$0.79($0.02)$1.46$640.96 million$637.00 million
8/8/2023Q2 2023$0.83$0.85+$0.02$1.32$538.52 million$545.00 million
5/9/2023Q1 2023$1.32$1.60+$0.28$2.64$914.72 million$1.13 billion
2/15/2023Q4 2022$1.56$1.56-$3.87$1.06 billion$1.06 billion
11/8/2022Q3 2022$0.71$0.73+$0.02$1.22$578.03 million$597.00 million
8/4/2022Q2 2022$0.78$0.79+$0.01$1.08$511.87 million$524.00 million
5/5/2022Q1 2022$0.72$0.61($0.11)$1.13$583.77 million$605.00 million
2/15/2022Q4 2021$0.79$0.80+$0.01$1.59$543.50 million$543.00 million    
11/10/2021Q3 2021$0.69$0.17($0.52)$1.29$568.92 million$587.00 million  
8/11/2021Q2 2021$0.70$0.71+$0.01$0.69$474.52 million$475.00 million
5/11/2021Q1 2021$0.65$0.67+$0.02$1.23$489.61 million$524.00 million  
2/17/2021Q4 2020$0.70$0.28($0.42)$0.28$486.89 million$572.00 million  












Royalty Pharma Earnings - Frequently Asked Questions

When is Royalty Pharma's earnings date?

Royalty Pharma has confirmed that its next quarterly earnings data will be published on Thursday, February 15th, 2024. Learn more on RPRX's earnings history.

Did Royalty Pharma beat their earnings estimates last quarter?

In the previous quarter, Royalty Pharma (NASDAQ:RPRX) missed the analysts' consensus estimate of $0.81 by $0.02 with a reported earnings per share (EPS) of $0.79. Learn more on analysts' earnings estimate vs. RPRX's actual earnings.

How much revenue does Royalty Pharma generate each year?

Royalty Pharma (NASDAQ:RPRX) has a recorded annual revenue of $2.24 billion.

How much profit does Royalty Pharma generate each year?

Royalty Pharma (NASDAQ:RPRX) has a recorded net income of $42.83 million. RPRX has generated $0.31 earnings per share over the last four quarters.

What is Royalty Pharma's price-to-earnings ratio?

Royalty Pharma (NASDAQ:RPRX) has a trailing price-to-earnings ratio of 94.39 and a forward price-to-earnings ratio of 6.90. The price/earnings-to-growth ratio is 2.46.

What is Royalty Pharma's EPS forecast for next year?

Royalty Pharma's earnings are expected to decrease from $4.24 per share to $3.77 per share in the next year, which is a -11.08% change.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:RPRX) was last updated on 2/12/2024 by MarketBeat.com Staff

My Account -